1. Home
  2. MCI vs DCTH Comparison

MCI vs DCTH Comparison

Compare MCI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barings Corporate Investors

MCI

Barings Corporate Investors

HOLD

Current Price

$20.08

Market Cap

426.8M

Sector

Finance

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.20

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCI
DCTH
Founded
1971
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
426.8M
350.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MCI
DCTH
Price
$20.08
$10.20
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$22.60
AVG Volume (30 Days)
40.4K
515.9K
Earning Date
01-01-0001
11-04-2025
Dividend Yield
8.46%
N/A
EPS Growth
N/A
N/A
EPS
1.82
0.03
Revenue
N/A
$79,603,000.00
Revenue This Year
N/A
$131.69
Revenue Next Year
N/A
$39.22
P/E Ratio
$9.88
$298.50
Revenue Growth
N/A
251.54
52 Week Low
$12.96
$8.12
52 Week High
$19.24
$18.23

Technical Indicators

Market Signals
Indicator
MCI
DCTH
Relative Strength Index (RSI) 38.76 58.13
Support Level $19.14 $9.92
Resistance Level $20.83 $10.40
Average True Range (ATR) 0.43 0.41
MACD -0.05 0.02
Stochastic Oscillator 33.34 57.55

Price Performance

Historical Comparison
MCI
DCTH

About MCI Barings Corporate Investors

Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: